4D Molecular Therapeutics Inc (FDMT) Stock Price, Quote & News

Company Profile

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degene...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 505 2680

Website: www.4dmoleculartherapeutics.com

Address:

5858 Horton Street, Suite 455, EmeryVille, United States

HedgeAlerts Nov. 14 at 6:46 PM

Hedge Alert Live - Protect Your Portfolio Contract: $FDMT $11.00 Put · NOV 21, 2025 Exp Entry Price: $0.85 - $4.90 Exit Price Target: $1.76 Profit Margin: +107% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

ReturnOfEsquire Nov. 14 at 5:01 PM

$FDMT

0 · Reply

ReturnOfEsquire Nov. 14 at 4:57 PM

$FDMT Thinking about OCUL more, even if it meets its superiority endpoint over afilbercept. I am not sure the trial design is persuasive. Either way, what FDMT is doing is very smart. It is improving standard of care instead of replacing it. The medical field is resistant to change. I expect we would have market dominance in the retinal space for a decade or more.

1 · Reply

ReturnOfEsquire Nov. 14 at 4:51 PM

$FDMT 30-day chart is still trending upward with higher lows.

0 · Reply

HedgeAlerts Nov. 14 at 8:06 AM

Hedge Alert Live - Protect Your Portfolio Contract: $FDMT $10.00 Put · NOV 21, 2025 Exp Entry Price: $0.40 - $0.50 Exit Price Target: $0.65 Profit Margin: +62% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

caronte Nov. 13 at 3:01 PM

$FDMT 40$ short term squeeze the shorts

0 · Reply

ReturnOfEsquire Nov. 12 at 4:15 AM

$FDMT Two-year, severe data suggests 4D-150 is durable. We'll be getting two-year data for treatment naive in mid-2026.

1 · Reply

RaKa82 Nov. 12 at 1:54 AM

$FDMT so much for my very short lived dream of loading up under $10

0 · Reply

ReturnOfEsquire Nov. 12 at 12:30 AM

$FDMT Program update given.

0 · Reply

ReturnOfEsquire Nov. 12 at 12:30 AM

$FDMT Corporate presentation was updated with specific data.

0 · Reply

4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

Nov 6, 2025, 4:05 PM EST - 8 days ago

4DMT to Participate in Jefferies 2025 London Healthcare Conference

Nov 6, 2025, 6:23 AM EST - 8 days ago

4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

Nov 6, 2025, 6:00 AM EST - 8 days ago

4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150's Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years

Oct 30, 2025, 11:02 PM EDT - 14 days ago

4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific

Oct 17, 2025, 4:05 PM EDT - 4 weeks ago

4DMT Announces New Employment Inducement Grants

Oct 14, 2025, 8:00 AM EDT - 4 weeks ago

4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference

Oct 13, 2025, 8:00 AM EDT - 4 weeks ago

4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation

Sep 30, 2025, 5:08 AM EDT - 6 weeks ago

4D Molecular Therapeutics: This Gene Therapy Company May Soon Surprise Investors

Sep 9, 2025, 6:13 PM EDT - 2 months ago

4D Molecular Therapeutics, Inc. (FDMT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 2, 2025, 8:00 AM EDT - 2 months ago

4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA Readiness

Aug 25, 2025, 8:00 AM EDT - 2 months ago

4DMT to Participate in Upcoming Investor Conferences

Aug 11, 2025, 8:00 AM EDT - 3 months ago

4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

Aug 6, 2025, 8:00 AM EDT - 3 months ago

4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 1, 2025, 10:29 AM EDT - 3 months ago

4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study

Jul 31, 2025, 4:05 PM EDT - 3 months ago

4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update

Jul 24, 2025, 8:00 AM EDT - 4 months ago

4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists

Jul 2, 2025, 4:05 PM EDT - 4 months ago

4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution

May 8, 2025, 4:05 PM EDT - 6 months ago

4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

May 1, 2025, 8:00 AM EDT - 7 months ago

4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME

Mar 10, 2025, 8:00 AM EDT - 8 months ago

4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD

Feb 28, 2025, 4:05 PM EST - 9 months ago

4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

Feb 18, 2025, 2:33 PM EST - 9 months ago

4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression

Feb 10, 2025, 10:26 AM EST - 9 months ago

Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study

Feb 8, 2025, 2:30 PM EST - 9 months ago

4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program

Nov 13, 2024, 4:05 PM EST - 1 year ago

4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

Nov 4, 2024, 11:00 AM EST - 1 year ago

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Encourages Investor Participation

Nov 2, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out

Oct 30, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Impacted Investors To Reach Out

Oct 28, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Take Part

Oct 18, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Encourages Investors To Help Investigate 4D Molecular Therapeutics Inc For Possible Securities Fraud

Oct 16, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Urges Investor Participation In An Investigation Into 4D Molecular Therapeutics Inc For Securities Fraud

Oct 14, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Urges Investors To Help Investigate Whether 4D Molecular Therapeutics Inc Committed Securities Fraud

Oct 12, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics Inc Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Impacted Investors To Reach Out

Oct 10, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics Inc Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Investor Participation

Oct 8, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics Inc Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out

Oct 6, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out

Oct 4, 2024, 12:35 PM EDT - 1 year ago

4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure

Oct 4, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Impacted Investors To Reach Out

$Shareholders Are Encouraged To Join The Schall Law Firm's Inquiry Into 4D Molecular Therapeutics Inc For Securities Related Infractions$

Oct 3, 2024, 11:00 AM EDT - 1 year ago

Shareholders Are Encouraged To Join The Schall Law Firm's Inquiry Into 4D Molecular Therapeutics Inc For Securities Related Infractions

HedgeAlerts Nov. 14 at 6:46 PM

0 · Reply

ReturnOfEsquire Nov. 14 at 5:01 PM

$FDMT

0 · Reply

ReturnOfEsquire Nov. 14 at 4:57 PM

1 · Reply

ReturnOfEsquire Nov. 14 at 4:51 PM

$FDMT 30-day chart is still trending upward with higher lows.

0 · Reply

HedgeAlerts Nov. 14 at 8:06 AM

0 · Reply

caronte Nov. 13 at 3:01 PM

$FDMT 40$ short term squeeze the shorts

0 · Reply

ReturnOfEsquire Nov. 12 at 4:15 AM

$FDMT Two-year, severe data suggests 4D-150 is durable. We'll be getting two-year data for treatment naive in mid-2026.

1 · Reply

RaKa82 Nov. 12 at 1:54 AM

$FDMT so much for my very short lived dream of loading up under $10

0 · Reply

ReturnOfEsquire Nov. 12 at 12:30 AM

$FDMT Program update given.

0 · Reply

ReturnOfEsquire Nov. 12 at 12:30 AM

$FDMT Corporate presentation was updated with specific data.

0 · Reply

ReturnOfEsquire Nov. 11 at 9:02 PM

$FDMT Nice volume today. Close was a bit soft, but it still gained almost a full dollar from the daily low.

0 · Reply

ReturnOfEsquire Nov. 11 at 5:50 PM

$FDMT 239K share buy

1 · Reply

IN0V8 Nov. 11 at 4:37 PM

$FDMT Watch / Opportunity Barclays cuts target price to $33 from $38 Chardan Capital Markets raises PT to $26 from $25 RBC raises target price to $32 from $26

0 · Reply

anachartanalyst Nov. 11 at 4:02 PM

$FDMT https://anachart.com/wp-content/uploads/ana_temp/1762876927_soc-img.jpg

0 · Reply

JarvisFlow Nov. 11 at 3:20 PM

RBC Capital updates rating for 4D Molecular Therapeutics ( $FDMT ) to Outperform, target set at 26 → 32.

0 · Reply

JarvisFlow Nov. 11 at 2:54 PM

Barclays updates rating for 4D Molecular Therapeutics ( $FDMT ) to Overweight, target set at 38 → 33.

0 · Reply

Emremumcu01 Nov. 11 at 2:45 PM

$FDMT Anyone slightly concerned ?

2 · Reply

JarvisFlow Nov. 11 at 1:16 PM

Chardan Capital updates rating for 4D Molecular Therapeutics ( $FDMT ) to Buy, target set at 25 → 26.

0 · Reply

ReturnOfEsquire Nov. 11 at 1:07 AM

$FDMT Still a lot of green candles in the weekly, so I'm not convinced people are selling.

1 · Reply

Emremumcu01 Nov. 10 at 8:18 PM

$FDMT The SP atm

0 · Reply

grizzly3 Nov. 10 at 5:03 PM

$FDMT Whales are smart creatures — they know when to surface and when to dive. Right now, they’re unloading quietly while clown-pumper caronte flaps on deck. They won’t touch this one again until Q4 2026.

0 · Reply

grizzly3 Nov. 10 at 4:55 PM

$FDMT Live from Fantasyland: clown-pumper caronte calls for $100 again — chart politely responds with another trip to the $9S.

0 · Reply

Market Cap	626.77M
Revenue (ttm)	40,000.00
Net Income (ttm)	-160.87M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-402,175.00%
Debt to Equity Ratio	0.00

Volume	774,600
Avg Vol	844,234
Day's Range	N/A - N/A
Shares Out	57.14M
Stochastic %K	25%
Beta	2.96
Analysts	Strong Sell
Price Target	$33.11